#USA #Clinical Trials #AI Model #Kognitic #Somerville, NJ

Kognitic's AI Model Revolutionizes Clinical Trial Predictions

In a groundbreaking study published in Foresight, Kognitic's neural network model has been shown to notably outclass traditional prediction methods for primary completion dates (PCD) of clinical trials. This advancement is poised to revolutionize how pharmaceutical companies approach drug development timelines and budget planning, with significant implications for the industry.

The research reveals that conventional estimates for PCD in clinical trials often deviate by a staggering median of 508 days. In contrast, Kognitic's AI model has managed to narrow this gap, bringing the error down to just 179 days. This change is not merely a statistical improvement; it represents a potential saving of millions of dollars for pharmaceutical companies, who often face costs that can escalate to anywhere between $600,000 to $8 million for each day a trial is delayed.

The study, titled "Neural Network Models to Predict Clinical Trial Completion," analyzed data from over 60,000 oncology clinical trials, which has allowed the AI to generate more reliable predictions. By taking into account various factors such as indication, phase, line of therapy, population demographics, biomarkers, and additional trial characteristics, the model can provide personalized insights into each trial's specific timeline.

This innovative AI-driven approach enables pharmaceutical companies to set more realistic project timelines, thus allowing for better resource allocation and financial management. Companies using Kognitic's model can anticipate competitor market entry timings with greater accuracy, ensuring that they are not only prepared for their own trials but can also strategize around the competitive landscape.

Pharmaceutical organizations across the sector are already integrating Kognitic's PCD prediction model into their strategic frameworks, particularly emphasizing competitive intelligence and timeline management through subscription-based access. These tools aid in making informed decisions regarding drug development strategies and future market actions.

Key Findings:

• - Reduction in Prediction Error: The precision of predicting timelines has improved dramatically, reducing the average error from 508 days down to 179 days.
• - Comprehensive Analysis: By leveraging a large dataset from over 60,000 oncology trials, Kognitic provides actionable insights for trial design and execution.
• - Cost Management: The accurate timelines allow companies to avoid costly delays, arming them with critical intelligence for resource planning and market entry strategies.

Beneficiaries of this Innovation

Kognitic’s tools primarily benefit competitive intelligence, research and development (R&D), business development (BD), and commercial teams as they navigate the complexities of planning for 2025. As companies strive for optimized operational strategies, Kognitic's AI provides an essential edge in an intensely competitive market.

For more information or to schedule a demo, interested parties can visit kognitic.com or reach out via email.

About Kognitic

Kognitic is transforming the landscape of predictive intelligence through its SaaS platform, specifically designed for pharmaceutical and biotech industries. Utilizing cutting-edge machine learning and natural language processing, the company provides real-time insights drawn from clinical trials and market trends, allowing top pharmaceutical manufacturers to expedite analysis processes significantly.

With Kognitic spearheading innovation in the industry, the future of clinical trials is not only smarter but also more efficient, paving the way for a new era of drug development.